AIHTA - Publications - Search - Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Oncology Fact Sheet Nr. 42.

[thumbnail of Oncology Fact Sheet Nr.42.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
97kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 300-378 Kidney
Language:English
Series Name:Oncology Fact Sheet Nr. 42
Deposited on:24 Mar 2021 16:52
Last Modified:24 Mar 2021 16:52

Repository Staff Only: item control page